MEDX Oncology East


Session 6: Personalizing Treatment Strategies in Leukemia

Thursday, September 7     4:15pm – 5:30pm

Description

Treating leukemia, particularly in the community setting is fraught with challenges and variations in care. While the rate of adaptation in this setting is historically slower than in academic settings, there are notable changes to the treatment paradigm for ALL, AML, and CLL that warrants education focusing on improving quality for patients with leukemia. Utilizing high-risk cytogenetics and mutational analysis to stratify patients for treatment, assessing safety and efficacy data by patient age, integrating novel agents, and evaluating treatment patterns to ensure guideline adherence and evidence-based practice is vital to improving patient outcomes.

Session Outline

Faculty will discuss 3 patient stories to highlight the factors that impact treatment decisions in leukemia. The presentation will be interactive featuring the use of iPads throughout the session. The following areas will be discussed:

  • Risk categorization and prognostic significance of FISH and cytogenetic testing
  • Case 1: Acute Lymphoblastic Leukemia
    • Current standard of care – Clinical practice guidelines
    • Novel mechanisms of action including CAR T-cell therapies
  • Case 2: Acute Myeloid Leukemia
    • Novel therapies for high-risk de novo AML
    • Emerging therapy for secondary AML
  • Case 3: Chronic Lymphocytic Leukemia
    • Strategies to treat and prevent resistance
    • Safety and efficacy data of available management options
    • Patient preferences: dosing administration, toxicities, cost of therapy, quality of life
  • Emerging efficacy and safety data from late-phase clinical trials of novel agents

Q&A Session and Presentation Roundup

CME Information

AMA PRA Category 1 Credits™

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ANCC

Elsevier is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Elsevier is provider approved by the Florida Board of Nursing, Provider #50-4681, and the California Board of Registered Nursing, Provider #CEP 3257.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the EOCME, Elsevier’s accredited Provider Unit, and Rockpointe Oncology. Elsevier designates this activity for 1.0 CNE credits.

ACPE

Pharmacists – The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy education as a provider of continuing pharmacy education.

The Potomac Center for Medical Education designates this educational activity for a maximum of 1.0 hour (0.10 CEUs) of continuing education credit (UAN: xxx).

This is an application-based activity.

Faculty Information

Coming Soon